NoGeneST™ Anti-PTK-7 Aptamer, aPTK-7 aptamer-1 sodium

Name: NoGeneST™ Anti-PTK-7 Aptamer, aPTK-7 aptamer-1 sodium
SKU: NRYF-0625-HZ59
Rating: 5 (1 reviews)

[CAT#: NRYF-0625-HZ59]

A DNA aptamer that targets the cancer biomarker Protein Tyrosine Kinase 7 (PTK7) for diagnostic and therapeutic applications.

Target:: PTK7

Type:: DNA

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

Product Overview

Description

This is a single-stranded DNA aptamer engineered to bind with high affinity and specificity to the extracellular domain of Protein Tyrosine Kinase 7 (PTK7). As PTK7 is frequently overexpressed on the surface of various cancer cells, including leukemia and colon cancer, this aptamer serves as a precise molecular recognition tool. It is used for cancer cell identification, in vivo imaging, and as a guiding agent for targeted drug delivery.

Type

DNA

Relevant Diseases

Cancer

Properties

Size

1 mg; 5 mg; 10 mg

Appearance

Supplied as a lyophilized white to off-white solid.

Purity

>90%

Shipping

Room temperature

Storage

Powder Form: Stable for 3 years when stored at -20°C.
In Solvent: Stable for 6 months when aliquoted and stored at -80°C

Research Use Only

For Research Use Only

Target Details

Target

PTK7

Full Name

Protein Tyrosine Kinase 7

Gene ID

5754

Uniprot ID

Q13308

Target Overview

Protein Tyrosine Kinase 7 (PTK7) is a transmembrane protein that is a member of the receptor protein tyrosine kinase family. However, it is classified as a "pseudokinase" because its intracellular kinase domain is catalytically inactive. PTK7 is involved in regulating crucial cellular processes like cell adhesion, migration, and polarity, particularly during embryonic development via the Wnt signaling pathway. Importantly, PTK7 is highly overexpressed in a wide variety of human cancers, and its presence is often associated with tumor progression and metastasis, making it a key biomarker and target for developing cancer-specific therapies.

Publications